Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus

Table 2 The effects of canagliflozin on anthropometric and laboratory data

Variables	Before treatment	3 month after treatment	6 month after treatment
Body weight, kg	69 ± 13	69 ± 13	67 ± 11*
VAT area, cm²	109 ± 44	97 ± 46*	101 ± 47
SAT area, cm²	193 ± 71	177 ± 81*	182 ± 82
Skeletal muscle weight, kg/m²	15 ± 2	15 ± 2	15 ± 2
Systolic blood pressure, mmHg	131 ± 16	131 ± 20	125 ± 22
Diastolic blood pressure, mmHg	73 ± 11	77 ± 10	72 ± 8
Heart rate, b.p.m	75 ± 11	76 ± 11	76 ± 17
Hematocrit, %	42 ± 5	43 ± 5*	45 ± 6**
Serum creatinine, mg/dL	0.8 ± 0.3	0.9 ± 0.3	0.9 ± 0.3
eGFR, ml/min./1.73 m²	65 ± 19	63 ± 20	62 ± 18
Urinary albumin, mg/g ceratinine	37 ± 54	26 ± 27	33 ± 32
LDL-choresterol, mg/dL	106 ± 36	114 ± 42	119 ± 44
HDL-cholesterol, mg/dL	58 ± 21	58 ± 19	60 ± 20
Triglyceride, mg/dL	189 ± 100	160 ± 88	170 ± 121
Uric acid, mg/dL	4.9 ± 1.3	4.2 ± 1.1**	4.2 ± 1.0**

eGFR estimated glomerular filtration rate, LDL low-density lipoprotein, HDL high-density lipoprotein, VAT visceral adipose tissue, SAT subcutaneous adipose tissue
Data are presented as mean ± standard deviation. * P < 0.05 vs before treatment, ** P < 0.01 vs before treatment

ISSN: 1758-5996